The **Anti-Mitochondrial Antibody (AMA) test** is a specialized blood test used primarily to diagnose Primary Biliary Cholangitis (PBC), a chronic and progressive autoimmune liver disease. Mitochondria serve as the energy powerhouses within cells, but in patients with PBC, the immune system mistakenly produces autoantibodies that target these structures. This autoimmune attack causes inflammation and scarring of the small bile ducts inside the liver, potentially leading to liver failure if left untreated.

A positive AMA test—particularly the highly specific AMA-M2 subtype—is detected in approximately 90% to 95% of individuals with PBC, making it a definitive diagnostic marker.

**Anti-Infliximab Antibodies (ATIs)** are immune proteins produced by the body that mistakenly target and neutralize infliximab, a biologic medication used to treat autoimmune conditions like Crohn's disease and rheumatoid arthritis.

When a patient develops ATIs, the antibodies bind to the drug, clearing it from the bloodstream much faster than normal. This primary response leads to a significant drop in drug efficacy, often causing a return of disease symptoms (loss of response). Additionally, the formation of these immune complexes increases the risk of acute infusion reactions, such as fever, chills, or rashes, during treatment.
An Anti-Infliximab Antibodies (ATI) diagnostic test measures the level of these neutralizing antibodies in a patient's blood, typically alongside infliximab drug levels. This dual assessment, known as therapeutic drug monitoring (TDM), is crucial when a patient is losing response to treatment.

The **Anti-Hepatitis E Virus (HEV) IgM** test is a serological blood test designed to detect Immunoglobulin M (IgM) antibodies, which the body produces in response to a sudden, acute Hepatitis E virus infection.

Because IgM antibodies appear early during the initial phase of exposure and typically decline within a few weeks to months, a positive or reactive result serves as a strong diagnostic indicator of a current or very recent infection. Clinicians rely on this critical marker to differentiate acute illness from historical exposure (IgG) and to promptly manage or monitor acute liver inflammation.

Firm, high-density foam roller provides excellent support and stability during stretching and recovery. Helps relax muscles, relieve tension, reduce soreness, improve flexibility, and increase mobility. Ideal for massaging feet, legs, shoulders, arms, and hands anytime, anywhere.

An **Anti-dsDNA Antibody (IFA) Serum** test utilizes Indirect Immunofluorescence Assay (IFA) technology to detect autoantibodies targeting double-stranded DNA. This specialized method often employs *Crithidia luciliae* as a substrate, providing a highly specific substrate (the kinetoplast) to definitively confirm a **Systemic Lupus Erythematosus (SLE)** diagnosis.

By visualizing the fluorescent staining patterns under a microscope, clinicians can accurately differentiate lupus from other autoimmune conditions. Because positive IFA results correlate strongly with active **lupus nephritis**, this serum test serves as a critical biomarker for monitoring disease severity, predicting renal flares, and guiding clinical immunosuppressive therapies.

An **Anti-dsDNA (Anti-double-stranded DNA) antibody** test detects autoantibodies that mistakenly target the genetic material inside a person's own cells. This test is highly specific and serving as a hallmark diagnostic marker for **Systemic Lupus Erythematosus (SLE)**, a chronic autoimmune disease.

Because anti-dsDNA levels fluctuate in tandem with disease activity, doctors frequently use this blood test to monitor **lupus flares** and assess the risk of organ damage. Elevated levels are particularly correlated with **lupus nephritis**, a serious complication involving kidney inflammation, making the test vital for managing and tailoring ongoing treatment strategies.

An **Anti-DNase B (Anti-Deoxyribonuclease B) Serum test** measures antibodies produced by the body in response to a group A *Streptococcus* bacterial infection. While a sore throat is the most common presentation, this specific test is exceptionally valuable for detecting recent **streptococcal skin infections (impetigo)**, where other tests like ASOT can sometimes fail.

Evaluating Anti-DNase B levels helps doctors confirm past strep exposure when investigating delayed, serious complications. These include **acute post-streptococcal glomerulonephritis** (a kidney inflammatory disorder) and **rheumatic fever**, ensuring patients receive the correct, targeted long-term care.

An **Anti-Chlamydia trachomatis IgM antibody** test detects the early immune response to *Chlamydia trachomatis*, a common bacterial sexually transmitted infection (STI). Because IgM is the first antibody the immune system produces during an infection, its presence in the blood typically indicates a **recent or active infection**.

While highly useful for identifying acute cases, IgM levels naturally decline as the body transitions to long-term immunity (IgG antibodies). Doctors often pair this test with other diagnostics, like PCR swab tests, to confirm active chlamydia, manage potential complications like pelvic inflammatory disease, and ensure accurate, timely treatment.

The **Anti-Chlamydia trachomatis IgG antibody test** is a serological assay used to detect past or chronic exposure to *Chlamydia trachomatis*, a common bacterial sexually transmitted infection.
Unlike IgM or PCR tests that identify active, acute infections, the presence of **IgG antibodies** indicates a long-term immune response. Because chlamydial infections are frequently asymptomatic, they can remain undetected for years. High or persistent IgG titers are clinically valuable for investigating long-term complications of untreated chlamydia, such as pelvic inflammatory disease (PID), fallopian tube damage, ectopic pregnancy, and unexplained infertility in women, or epididymitis in men.

The **Anti-CCP (Anti-Cyclic Citrullinated Peptide) test** is a highly specific blood test used primarily to diagnose **Rheumatoid Arthritis (RA)**. It detects autoantibodies that mistakenly target citrullinated proteins, which are formed during joint inflammation.
With a specificity of over 95%, a positive result strongly indicates RA, helping physicians differentiate it from other forms of arthritis early in the disease course. Furthermore, elevated anti-CCP levels are strong prognostic indicators, often predicting a more aggressive, erosive form of joint damage. Early detection via this panel allows for timely therapeutic intervention, significantly improving long-term joint outcomes.

An **ankle tissue large biopsy (3–6 cm)** is a surgical procedure where a substantial sample of skin, subcutaneous fat, fascia, or deep soft tissue is excised from the ankle region. Typically performed under local or regional anesthesia, this procedure targets larger, deep-seated lesions, chronic non-healing ulcers, or suspected soft-tissue masses.
Given the ankle's complex anatomy—characterized by dense tendons, major ligaments, and limited skin elasticity—a 3–6 cm excision requires precise surgical handling and meticulous wound closure to ensure proper healing. The harvested specimen is submitted for histopathological evaluation to diagnose inflammatory conditions, deep infections, or neoplastic growths.